1 – 50 of 67
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
(
- Contribution to journal › Article
-
Mark
Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
(
- Contribution to journal › Article
-
Mark
Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition
(
- Contribution to journal › Article
-
Mark
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
(
- Contribution to journal › Article
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
(
- Contribution to journal › Article
-
Mark
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
2019) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
(
- Contribution to journal › Article
- 2018
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
-
Mark
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
(
- Contribution to journal › Article
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Body composition measurements and risk of hematological malignancies : A population-based cohort study during 20 years of followup
(
- Contribution to journal › Article
-
Mark
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : A multicentre, open-label, single-arm, phase 2 trial
(
- Contribution to journal › Article
-
Mark
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
-
Mark
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Newly diagnosed and relapsed mantle cell lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
-
Mark
Targeting of B-cell receptor signalling in B-cell malignancies
(
- Contribution to journal › Scientific review
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
-
Mark
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
(
- Contribution to journal › Article
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration
(
- Contribution to journal › Article
-
Mark
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
- 2015
-
Mark
Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.
(
- Contribution to journal › Article
-
Mark
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
(
- Contribution to journal › Article
-
Mark
Emerging role of SOX11 in mantle cell lymphoma
(
- Contribution to journal › Scientific review
-
Mark
The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
(
- Contribution to journal › Article
-
Mark
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article
-
Mark
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
(
- Contribution to journal › Article
-
Mark
Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.
(
- Contribution to journal › Article
-
Mark
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
(
- Contribution to journal › Article
-
Mark
Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.
(
- Contribution to journal › Article
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
-
Mark
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
2015) In Hematological Oncology(
- Contribution to journal › Article